17,261 trials
Alzheimer's Disease · Dementia · Memory Loss
Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67
Parkinson's Disease
Primary: The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 — 78.9; 31.6; 78.9; 68.4 percentage of participants
Tumor Induced Osteomalacia (TIO) · Epidermal Nevus Syndrome (ENS)
Primary: Percentage of Participants Achieving Mean Serum Phosphorus Levels Above 2.5 mg/dL at the Mid-Point of the Dose Intervals Between Baseline and Week 24 — 50.0 percentage…
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Nausea and Vomiting, Postoperative · Nausea With Vomiting Chemotherapy-Induced
Primary: Cmax — 37.282; 41.108 ng/mL
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Progression-Free Survival (PFS) at 4 Months — 52.17 percentage of patients alive
Multiple Sclerosis, Primary Progressive · Multiple Sclerosis, Secondary Progressive
Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04
Heart Failure · Cardiac Failure · Reduced Ventricular Ejection Fraction
Primary: Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231…
Type 1 Diabetes
Primary: Change in GAD65 Autoantibody Titer (DK Units/mL) — 247; 234; 193; 196 DK Units/mL
Vasculitis
Primary: Proportion of Subjects Achieving Disease Response at Day 85 — 0.7; 0.86; 0.81 proportion of participants
Alcohol Dependence
Primary: Percentage of Heavy Drinking Days (HDD%) During the Full Dose Period From Weeks 3-12 — 8.2; 27.11; 31.29; 7.32 percentage of heavy drinking days — p=0.016
Neuroendocrine Tumors · Pancreatic Neoplasms
Primary: Objective Response Rate — 3; 14 Participants
Postoperative Nausea and Vomiting
Primary: Number of Participants With Nausea and/or Vomiting — 10; 26 Participants — p=0.003
Heart Failure
Primary: Exercise Capacity as Measured by Peak Oxygen Uptake (Peak VO2) — 9.1; 9.8 mL/kg/min — p=0.053
Human Immunodeficiency Virus · Coronary Artery Disease
Primary: Coronary Endothelial Function as Assessed by Percent Coronary Artery Area Change With Isometric Handgrip Exercise — 5.6 percent change in coronary artery area